UnitedHealth (UNH) Stock Slides as Revenue Decline, Optum Losses and DOJ Scrutiny Shake Wall Street

UnitedHealth (UNH) Stock Slides as Revenue Decline, Optum Losses and DOJ Scrutiny Shake Wall Street

Shares of UnitedHealth Group (UNH) slipped as investors reacted to a combination of operational challenges, regulatory scrutiny, and a rare slowdown in revenue growth.

The stock recently traded near $286, down about 0.80%, as company-specific concerns weighed on sentiment.

The broader market also struggled during the session. The S&P 500 declined roughly 1.2%, while the healthcare sector slipped about 0.68%, meaning UnitedHealth’s drop slightly underperformed its sector peers.

Operational Reset After Revenue Decline

UnitedHealth is currently undergoing a major operational reset after reporting its first revenue decline in more than a decade.

The slowdown has been largely tied to losses in the company’s healthcare services division, Optum, along with weakening membership trends in certain insurance segments.

To address the pressure, the company has introduced cost-control measures including:

  • Salary increases limited to 0–2%
  • Planned layoffs across divisions
  • A target of about $1 billion in operating cost reductions

These measures are aimed at stabilizing margins and restoring earnings growth.

Optum Health Losses Raise Investor Concerns

The biggest operational pressure is coming from Optum Health, which has reported significant losses.

Optum has historically been a key growth engine for UnitedHealth, providing healthcare analytics, pharmacy benefit management, and care delivery services. Weakness in this division has therefore become a major concern for investors assessing the company’s future earnings strength.

Medicare Advantage Membership Decline

Another headwind comes from the Medicare Advantage segment.

UnitedHealth has experienced declining membership in this program, a notable development because Medicare Advantage has been one of the company’s most important long-term growth drivers.

Changes in regulatory oversight and reimbursement structures are making the market more competitive and complex for insurers.

Legal and Regulatory Scrutiny

UnitedHealth is also dealing with legal pressures that are adding to investor uncertainty.

The company is facing Department of Justice investigations and a class-action lawsuit tied to pricing and healthcare practices. Regulatory scrutiny increases the company’s operational risk profile and could potentially lead to higher compliance costs.

Recent healthcare policy discussions have also placed the industry under closer review, as highlighted in coverage from Bloomberg.

Insider Transactions

Recent filings showed 17 insider transactions reported on February 23, 2026, totaling approximately $2.7 million.

The activity included:

  • 13 stock awards
  • 4 tax-related share withholding transactions

One major grant involved 8,855 shares awarded to Wayne S. DeVeydt, valued at about $2.5 million, representing the majority of the reported transaction value.

Earnings Outlook

Analysts expect mixed results in the upcoming quarter.

  • EPS forecast: $6.76 per share
  • Year-over-year change: –6.11%
  • Projected revenue: $110.26 billion
  • Revenue growth: +0.62%

The outlook suggests that revenue remains relatively stable, but profit margins are under pressure.

Valuation Signals

Despite the challenges, valuation metrics suggest the stock may offer potential upside.

UnitedHealth shares are currently trading around $291 compared with an average analyst price target of $364.63, implying roughly 25% upside.

The company’s price-to-earnings ratio has also declined from 21.67x in early 2025 to about 17.78x, making the stock cheaper relative to historical levels.

Some valuation models have even suggested the shares could be trading about 64.3% below estimated fair value.

Key areas Wall Street is watching:

  • Optum profit margins
  • Medicare Advantage membership trends
  • Progress on cost-cutting measures
  • Developments in regulatory investigations

UnitedHealth remains one of the most influential companies in the healthcare industry, but the current operational reset has placed the stock under intense scrutiny from Wall Street.

Add Swikblog as a preferred source on Google

Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.